The best meta-analysis (with individual patient data) did not find a mortality benefit in those at high risk but without prior cardiovascular disease.

There was no mortality benefit in women.

The distribution of mortality benefits by pollutant, source, and region is presented in Table 4, with identical patterns seen for the morbidity outcomes.

Many have no data on mortality benefit or time to progression.

Revascularization for acute coronary syndrome has a significant mortality benefit.

For example, does letrozole lead to a mortality benefit?

Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma.

One review did not find a mortality benefit in those at high-risk but without prior cardiovascular disease.

Other reviews concluded that there is a mortality benefit but concerns regarding the quality of the evidence persist.

The new study showed that women with one or more risk factors for heart disease were likely to derive the greatest mortality benefit from hormone replacement.